Clinical efficacy of Ginkgo biloba diterpenoid lactone glucosamine combined with edaravone dextrogenol in the treatment of acute ischemic stroke
10.3760/cma.j.cn341190-20240201-00143
- VernacularTitle:银杏二萜内酯葡胺联合依达拉奉右莰醇治疗急性缺血性脑卒中效果观察
- Author:
Haiying ZHANG
1
;
Juwei ZHANG
Author Information
1. 胶州市九龙医院急诊内科，青岛 266300
- Keywords:
Stroke;
Hypoxia-ischemia, brain;
Drug therapy, combination;
Nervous system diseases;
National institute of neurological disorders and stroke;
C-reactive pr
- From:
Chinese Journal of Primary Medicine and Pharmacy
2024;31(9):1333-1338
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of Ginkgo biloba diterpenoid lactone glucosamine combined with edaravone dextrogenol in the treatment of acute ischemic stroke in patients as well as its effect on neurological function and levels of inflammatory factors.Methods:A retrospective case-control study was conducted on the clinical data of 86 patients with acute ischemic stroke who received treatment at Jiulong Hospital of Jiaozhou from December 2021 to October 2023. The patients were divided into two groups based on their treatment regimens, with 43 patients in each group. Both groups received standardized conventional treatment. The control group received additional treatment with edaravone dextrogenol, while the observation group was given Ginkgo biloba diterpenoid lactone glucosamine in addition to the treatments provided to the control group. All patients were treated for 14 days. The clinical efficacy of both groups was assessed. The National Institutes of Health Stroke Scale score, serum C-reactive protein level, and lipoprotein-associated phospholipase A2 level were compared before and after treatment. The incidence of adverse reactions during the whole treatment period was compared between the two groups.Results:After 14 days of treatment, the National Institutes of Health Stroke Scale score in the observation group was (7.09 ± 2.15) points, which was significantly lower than that of the control group [(8.23 ± 2.97) points, t = -2.04, P = 0.045]. The clinical efficacy of the observation group was significantly superior to that of the control group ( Z = 1.62, P = 0.011). The serum levels of C-reactive protein and lipoprotein-associated phospholipase A2 in the observation group were (14.53 ± 5.05) mg/L and (169.95 ± 17.62) μg/L, respectively, which were significantly lower than those in the control group [(16.88 ± 5.46) mg/L, (178.53 ± 20.34) μg/L, t = -2.07, -2.09, P = 0.047, 0.040]. There was no significant difference in the incidence of adverse reactions between the two groups (χ2 = 0.09, P = 0.763). Conclusion:The combination of Ginkgo biloba diterpenoid lactone glucosamine and edaravone dextrogenol for the treatment of acute ischemic stroke in patients is effective and reliable. This combined therapy exhibits a good neuroprotective effect, helps improve neurological function, reduces inflammatory responses, and does not increase the incidence of adverse reactions.
